**List of Supplementary Figures**

Fig. S1. Full Western blot images for analysis of autophagy and MHC I expression.

Fig. S2. Activity of pegzilarginase in model tumors.

Fig. S3. Pegzilarginase induces immunogenic cell death *in vivo.*

Fig. S4. Pegzilarginase does not alter the percent of total live cells.

Fig. S5. Pegzilarginase does not induce apoptosis in systemic CD8+ T cells or the compensatory gene pathway in CD8+ T cells.

Fig. S6. Pegzilarginase induces autophagy genes in CD45- cells.

Fig. S7. Pegzilarginase induces MHC I and MHC II expression *in vitro*.

Fig S8. Combination therapy with pegzilarginase and aCTLA-4 does not significantly improve efficacy over monotherapies.

Fig. S9. Gating strategy for introtumoral CD4+ and CD8+ T lymphocytes.

Fig. S10. Immunophenotyping of CT26 tumors treated with pegzilarginase and/or aPD-L1.

Fig. S11. Pegzilarginase/aOX40 combination therapy induces CD8+ T cell exhaustion, activation, and ROS metabolism genes.

Fig. S12. Pegzilarginase/aOX40 combination therapy dramatically alters the TME.

Fig. S13. Pegzilarginase/aOX40 combination therapy alters innate cell phenotypes.

Table S1. Metabolite Standards Table